var data={"title":"Didanosine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Didanosine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6023?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=didanosine-drug-information\" class=\"drug drug_general\">see &quot;Didanosine: Drug information&quot;</a> and <a href=\"topic.htm?path=didanosine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Didanosine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708701\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pancreatitis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fatal and nonfatal pancreatitis have occurred during therapy with didanosine used alone or in combination regimens in both treatment-naive and treatment-experienced patients, regardless of the degree of immunosuppression. Suspend didanosine in patients with suspected pancreatitis; discontinue didanosine in patients with confirmed pancreatitis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Lactic acidosis/severe hepatomegaly:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination, including didanosine and other antiretrovirals. Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine with other antiretroviral agents. Coadministration of didanosine and stavudine is contraindicated because of increased risk of serious and/or life-threatening events. Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159665\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Videx;</li>\n      <li>Videx EC</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159666\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Videx EC</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052239\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiretroviral Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">HIV Agents (Anti-HIV Agents)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Nucleoside Reverse Transcriptase Inhibitor (NRTI)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442298\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 infection, treatment:</b> Use in combination with other antiretroviral agents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &lt;14 days: Dose not established; pharmacokinetic parameters are too variable to determine appropriate dosage</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &ge;14 days: Oral solution: 50 mg/m<sup>2</sup>/dose every 12 hours. <b>Note:</b> Manufacturer's labeling not recommended (100 mg/m<sup>2</sup>/dose); pharmacokinetic data suggest toxicity may occur at this higher dose (HHS [pediatric] 2016) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment</b>: Insufficient data exists to recommend a specific dosage adjustment; however, a decrease in the dose should be considered in pediatric patients with renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052232\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=didanosine-drug-information\" class=\"drug drug_general\">see &quot;Didanosine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 infection, treatment:</b> Oral: Use in combination with other antiretroviral agents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 1 to 8 months (HHS [pediatric] 2016): Oral solution:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants 1 to &lt;3 months: 50 mg/m<sup>2</sup>/dose every 12 hours. <b>Note:</b> Manufacturer's labeling not recommended (100 mg/m<sup>2</sup>/dose); pharmacokinetic data suggest toxicity may occur at this higher dose (HHS [pediatric] 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;3 to 8 months: 100 mg/m<sup>2</sup>/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &gt;8 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral solution:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer's labeling: 120 mg/m<sup>2</sup>/dose every 12 hours; do not exceed weight-based adult dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">AIDS<i>info</i> recommendation (HHS [pediatric] 2016): 120 mg/m<sup>2</sup>/dose (range: 90 to 150 mg/m<sup>2</sup>/dose) every 12 hours; do not exceed weight-based adult dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Alternate once-daily dosing for treatment-naive children &ge;3 year and Adolescents: 240 mg/m<sup>2</sup>/dose once daily; maximum dose: 400 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Delayed release capsule: Children &ge;6 years weighing &ge;20 kg who are able to swallow a capsule whole:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 kg to &lt;25 kg: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">25 kg to &lt;60 kg: 250 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;60 kg: 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for concomitant tenofovir therapy:</b> There are no pediatric-specific recommendations; in adult patients, dosing adjustment suggested.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>HIV-1 infection, treatment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dosing based on patient weight:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Pediatric powder for oral solution: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;60 kg: 125 mg twice daily (preferred) or 250 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;60 kg: 200 mg twice daily (preferred) or 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Delayed release capsule: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">25 kg to &lt;60 kg: 250 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;60 kg: 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for concomitant therapy:</b> When taken with tenofovir: Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;60 kg and CrCl &ge;60 mL/minute: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;60 kg and CrCl &ge;60 mL/minute: 250 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;60 mL/minute: Dose has not been established</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: Insufficient data exists to recommend a specific dosage adjustment; however, a decrease in the dose should be considered in pediatric patients with renal impairment. The following guidelines have been used by some clinicians (Aronoff 2007): Oral solution:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 75 mg/m<sup>2</sup>/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 90 mg/m<sup>2</sup>/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 75 mg/m<sup>2</sup>/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: 75 mg/m<sup>2</sup>/dose every 24 hours after dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: 75 mg/m<sup>2</sup>/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): 75 mg/m<sup>2</sup>/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Dosing based on patient weight, creatinine clearance, and dosage form:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosing for patients &lt;60 kg: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;60 mL/minute: No dosage adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 59 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral solution: 75 mg twice daily or 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Delayed release capsule: 125 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 29 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral solution: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Delayed release capsule: 125 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral solution: 75 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Delayed release capsule: Use alternate formulation</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosing for patients &ge;60 kg: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;60 mL/minute: No dosage adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 59 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral solution: 100 mg twice daily or 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Delayed release capsule: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 29 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral solution: 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Delayed release capsule: 125 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral solution: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Delayed release capsule: 125 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosing adjustment in patients requiring continuous ambulatory peritoneal dialysis (CAPD) or hemodialysis:</i> Use dosing recommendations for patients with CrCl &lt;10 mL/minute; supplemental doses following hemodialysis are not needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No adjustment recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159637\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Videx EC: 125 mg, 200 mg, 250 mg, 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg [DSC], 200 mg, 250 mg, 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Videx: 2 g (100 mL); 4 g (200 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159622\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9845084\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Videx: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020156s053lbl.pdf#page=32&amp;token=kNs203EzMGXAnGpMli9FhaGhoWCOj9cwGfw8lfvc4ABH84NbLxLHVXT0V01OZ9ZcFoyyxqKkOQT7ks5+y/PsIuv5nYIsoDewWUdZtB1nx6bA5ez2FJSdekbtZRuYXlVW&amp;TOPIC_ID=12691\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020156s053lbl.pdf#page=32</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Videx EC: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM199212.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQL2+4Iuh5lNAZY9w5VINFyg==&amp;TOPIC_ID=12691\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM199212.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052243\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer oral solution and delayed release capsule on an empty stomach 30 minutes before or at least 2 hours after a meal. Some experts have recommended giving without regard to meals in order to improve compliance (HHS [pediatric] 2016). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Shake well before use. The solution contains antacids that may interfere with the absorption of other medications; see dosage interactions field for appropriate dosage spacing for administration of concomitant medications. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delayed release capsule: Swallow capsule whole; do not break open or chew. If administered with tenofovir, the delayed release capsule may be administered with a light meal or in the fasted state. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Undergoes rapid degradation when exposed to an acidic environment; 10% of the drug decomposes to hypoxanthine in &lt;2 minutes at pH &lt;3 at 37&deg;C. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159659\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Delayed release capsules should be stored in tightly closed bottles at controlled room temperature of 25&deg;C (77&deg;F). Unreconstituted powder should be stored at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); reconstituted oral solution is stable for 30 days stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052242\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of HIV-1 infection in combination with other antiretroviral agents (Oral solution: FDA approved in ages &ge;2 weeks and adults; Delayed release capsule: FDA approved in ages &ge;6 years weighing &ge;20 kg and adults); <b>Note:</b> HIV regimens consisting of <b>three</b> antiretroviral agents are strongly recommended</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159715\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Videx may be confused with Bidex, Lidex</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159713\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As reported in monotherapy studies; risk of toxicity may increase when combined with other agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Peripheral neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased amylase, increased uric acid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, pancreatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute renal failure, alopecia, anaphylactoid reaction, anemia, anorexia, arthralgia, chills, diabetes mellitus, dyspepsia, fever, flatulence, hepatic failure, hepatitis, hyperglycemia, hypoglycemia, increased creatine phosphokinase, increased gamma-glutamyl transferase, lactic acidosis, leukopenia, lipoatrophy (buttocks, face, limbs), myalgia, myopathy, optic neuritis, pain, parotid gland enlargement, portal hypertension (noncirrhotic), retinal pigment changes (depigmentation), rhabdomyolysis, severe hepatomegaly with steatosis, sialadenitis, symptomatic hyperlactatemia, thrombocytopenia, weakness, xerophthalmia, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159644\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coadministration with allopurinol, ribavirin, or stavudine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to didanosine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159626\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactic acidosis/hepatomegaly: <b>[US Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported, including fatal cases, with nucleoside analogues, alone or in combination, including didanosine and other antiretrovirals.</b> Risk may be increased with female gender, obesity, or prolonged exposure. Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine with other antiretroviral agents. According to the manufacturer, the combination of didanosine and stavudine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk. However, current guidelines note that this combination should not be used in pregnant females with HIV (HHS [perinatal] 2017). Use caution when administering to patients with known risk factors for liver disease. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lipoatrophy: May cause loss of subcutaneous fat, especially in the face, limbs, and buttocks. Lipoatrophy incidence and severity are related to cumulative exposure and may be only partially reversible. Monitor patients for signs of lipoatrophy and consider switching to a nondidanosine-containing regimen if lipoatrophy occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Noncirrhotic portal hypertension: Patients may develop noncirrhotic portal hypertension within months to years of starting didanosine therapy. Signs may include elevated liver enzymes, esophageal varices, hematemesis, ascites, and splenomegaly. Noncirrhotic portal hypertension may lead to liver failure and/or death. Discontinue use in patients with evidence of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Retinal changes (including retinal depigmentation) and optic neuritis have been reported in adults and children using didanosine; patients should undergo retinal examination periodically.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: <b>[US Boxed Warning]: Pancreatitis (fatal and nonfatal) has been reported alone or in combination regimens in both treatment-naive and treatment-experienced patients, regardless of degree of immunosuppression. Suspend use in patients with suspected pancreatitis and discontinue in patients with confirmed pancreatitis;</b> frequency is dose related. In patients with risk factors for pancreatitis, use with extreme caution and only if clearly indicated. Patients with advanced HIV-1 infection, especially the elderly, are at increased risk and should be followed closely. Patients with renal impairment may be at greater risk for pancreatitis if treated without dose adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral neuropathy: Peripheral neuropathy (numbness, tingling or pain in the hands or feet) has been reported, more frequently in patients with advanced HIV disease, in patients with a history of neuropathy or in patients being treated with a neurotoxic drug. Discontinue therapy if neuropathy occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; safety and efficacy have not been established in patients with significant hepatic disease. Patients on combination antiretroviral therapy with hepatic impairment may be at increased risk of potentially severe and fatal hepatic toxicity; consider interruption or discontinuation of therapy if hepatic impairment worsens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dose reduction recommended for CrCl &lt;60 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hydroxyurea and stavudine: Fatal cases of hepatotoxicity/lactic acidosis and/or severe peripheral neuropathy have been reported in HIV patients treated with didanosine with hydroxyurea and stavudine; avoid use with hydroxyurea; coadministration with stavudine is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tenofovir: Combined use may be associated with increased didanosine toxicity (eg, lactic acidosis, pancreatitis), immunologic nonresponse or CD4 cell decline despite viral suppression, early virologic failure and rapid resistance development; combined use is not recommended (HHS [adult], 2015); manufacturer labeling recommends a didanosine dose reduction if combination is used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Additional potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delayed-release capsules: Didanosine delayed-release capsules are indicated for once-daily use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Powder for oral solution: Didanosine powder for oral solution is recommended for use in a twice daily regimen, as there is more efficacy evidence with twice daily administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric: Dosing recommendations for didanosine powder for oral solution in patients younger than 2 weeks cannot be made because the pharmacokinetics of didanosine in these infants are too variable to determine an appropriate dose. Delayed-release capsules may be used in pediatric patients who weigh at least 20 kg.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855998\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Fatal and nonfatal pancreatitis is more common in adults than children (1% to 7% vs 3% [normal doses]). Retinal depigmentation in children receiving doses &gt;300 mg/m<sup>2</sup>/day may occur; retinal changes and optic neuritis have been reported in pediatric and adult patients; perform periodic retinal examinations. Due to an increased risk of serious toxicities, the combined use of stavudine and didanosine is not recommended for use in adults and adolescents (HHS [adult] 2015) and is not recommended as part of an initial antiretroviral regimen in pediatric patients; however, it may be considered for use in pediatric regimens if the potential benefit clearly outweighs the risks (HHS [pediatric] 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299187\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159631\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12691&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Didanosine. Specifically, the risk of pancreatitis may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May increase the serum concentration of Didanosine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): Didanosine may decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals. <b> Exceptions: </b>Isavuconazonium Sulfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Didanosine may decrease the serum concentration of Atazanavir. Specifically, the buffered formulation of didanosine may decrease atazanavir absorption. Atazanavir may decrease the serum concentration of Didanosine. Reported with enteric coated didanosine capsules.  Management: To avoid therapeutic failure of atazanavir the drug should be administered 2 hours before or 1 hour after didanosine.  This recommendation applies to both buffered didanosine products and enteric coated didanosine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May decrease the serum concentration of Didanosine. More specifically, this interaction is likely due to the effects of food (with which darunavir/ritonavir and darunavir/cobicistat are taken) on didanosine, which is supposed to be given on an empty stomach. Management: Didanosine should be administered 1 hour prior to or 2 hours after administration of darunavir/ritonavir or darunavir/cobicistat (which must be taken with food).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Febuxostat: May increase the serum concentration of Didanosine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: May increase the serum concentration of Didanosine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxyurea: Didanosine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. Hydroxyurea may enhance the adverse/toxic effect of Didanosine. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Didanosine may decrease the serum concentration of Indinavir.  Management: Indinavir should be administered on an empty stomach at least 1 hour apart from administration of buffer-containing formulations of didanosine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May decrease the serum concentration of Didanosine. This interaction refers only to lopinavir/ritonavir oral solution, which must be taken with food, and is principally the result of a food-didanosine interaction. Management: Didanosine should be administered 1 hour prior to or 2 hours after administration of lopinavir/ritonavir oral solution (which must be taken with food).  Didanosine and lopinavir/ritonavir tablets can be administered together.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: May decrease the serum concentration of Didanosine. Management: If use of methadone with didanosine is necessary, enteric coated didanosine is preferred.  Avoid using didanosine powder for solution with methadone.  Increased monitoring of clinical response to didanosine (including viral load) is necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May decrease the serum concentration of Didanosine. Didanosine may decrease the serum concentration of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Oral Inhalation): May enhance the adverse/toxic effect of Didanosine. Ribavirin (Oral Inhalation) may increase serum concentrations of the active metabolite(s) of Didanosine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Systemic): May enhance the adverse/toxic effect of Didanosine. Ribavirin (Systemic) may increase serum concentrations of the active metabolite(s) of Didanosine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: May decrease the absorption of Didanosine. More specifically, simultaneous coadministration of these drugs creates a conflict between recommendations to administer with (rilpivirine) and without (didanosine) food. Didanosine may decrease the absorption of Rilpivirine. More specifically, simultaneous coadministration of these drugs creates a conflict between recommendations to administer with (rilpivirine) and without (didanosine) food. Management: Administer didanosine on an empty stomach at least 2 hours before or 4 hours after rilpivirine, due to the requirement that rilpivirine be administered with food.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stavudine: May enhance the adverse/toxic effect of Didanosine. The risk of lactic acidosis (possibly fatal), hepatomegaly, and pancreatitis may be increased with this combination.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Disoproxil Fumarate: May diminish the therapeutic effect of Didanosine. Tenofovir Disoproxil Fumarate may increase the serum concentration of Didanosine. Management: Avoid concomitant treatment with tenofovir disoproxil fumarate and didanosine.  Consider altering even existing, stable treatment to avoid this combination.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May decrease the serum concentration of Didanosine. Management: It is recommended that didanosine be administered at least 2 hours apart from tipranavir in order to minimize any potential dosage form-related interaction.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159661\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases AUC and C<sub>max</sub>; serum levels may be decreased by 55%. Management: Administer on an empty stomach at least 30 minutes before or 2 hours after eating depending on dosage form.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159633\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159648\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Didanosine has a low to moderate level of transfer across the human placenta. Based on data from the Antiretroviral Pregnancy Registry, an increased rate of birth defects has been observed following maternal use of didanosine during the first trimester and later during pregnancy; no pattern of defects has been observed and clinical relevance is uncertain. Maternal antiretroviral therapy (ART) may increase the risk of preterm delivery, although available information is conflicting possibly due to variability of maternal factors (disease severity; gestational age at initiation of therapy); however, maternal antiretroviral medication should not be withheld due to concerns of preterm birth. Information related to stillbirth, low birth weight, and small for gestational age infants is limited. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children who develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential mitochondrial dysfunction.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>[US Boxed Warning]: Fatal lactic acidosis has been reported in pregnant women using didanosine and stavudine in combination with other antiretroviral agents.</b> According to the manufacturer, this combination should be used with caution during pregnancy and only if the potential benefit clearly outweighs the potential risk; however, current guidelines note that this combination should not be used in pregnant females with HIV. Cases of lactic acidosis and hepatic steatosis related to mitochondrial toxicity have been reported with use of nucleoside reverse transcriptase inhibitors (NRTIs). These adverse events are similar to other rare but life-threatening syndromes that occur during pregnancy (eg, HELLP syndrome). In addition to lactic acidosis, the combination of didanosine and stavudine has been shown to increase the risk of birth defects and neurodevelopmental disability.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Health and Human Services (HHS) Perinatal HIV Guidelines do not recommend didanosine for initial therapy in antiretroviral-naive pregnant females due to toxicity. In addition, because of the high risk of toxicity, didanosine should be stopped in females who become pregnant during therapy and women should be switched to a preferred or alternative regimen.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, ART is recommended for all pregnant females with HIV to keep the viral load below the limit of detection and reduce the risk of perinatal transmission. When HIV is diagnosed during pregnancy in a female who has never received antiretroviral therapy, ART should begin as soon as possible after diagnosis. Females who become pregnant on a stable ART regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated. Monitoring during pregnancy is more frequent than in nonpregnant adults; ART should be continued postpartum for all females living with HIV.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll pregnant females exposed to antiretroviral medications as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263 or http://www.APRegistry.com). Health care providers caring for HIV-infected females and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052238\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The absolute CD4 cell count is currently recommended to monitor immune status in children of all ages; CD4 percentage can be used as an alternative in children &lt;5 years of age. This recommendation is based on the use of absolute CD4 cell counts in the current pediatric HIV infection stage classification and as thresholds for urgency of initiation of antiretroviral treatment (HHS [pediatric] 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Prior to initiation of therapy: Genotypic resistance testing, CD4 and viral load (every 3 to 4 months), CBC with differential, LFTs, BUN, creatinine, electrolytes, glucose, urinalysis (every 6 to 12 months), and assessment of readiness for adherence with medication regimen. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, urinalysis (at initiation), BUN, creatinine, albumin, total protein, lipid panel (at initiation), CD4, and viral load. After 1 to 2 weeks of therapy: Signs of medication toxicity and adherence. After 2 to 4 weeks of therapy: CBC with differential, viral load, signs of medication toxicity, and adherence; then every 3 to 4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, viral load, signs of medication toxicity, and adherence. Lipid panel and urinalysis every 6 to 12 months. CD4 monitoring frequency may be decreased to every 6 to 12 months in children who are adherent to therapy if the value is well above the threshold for opportunistic infections, viral suppression is sustained, and the clinical status is stable for more than 2 to 3 years. In patients with known or suspected complex drug resistance patterns, phenotypic resistance testing (usually in addition to genotypic resistance testing) should be performed (HHS [pediatric] 2017). Monitor for growth and development, signs of HIV-specific physical conditions, HIV disease progression, opportunistic infections, peripheral neuropathy, pancreatitis, or lactic acidosis</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">To monitor for portal hypertension: CBC with platelet count, splenomegaly on physical exam, liver enzymes, serum bilirubin, albumin, INR, ultrasound</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159625\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Didanosine, a purine nucleoside (adenosine) analog and the deamination product of dideoxyadenosine (ddA), inhibits HIV replication <i>in vitro</i> in both T cells and monocytes. Didanosine is converted within the cell to the mono-, di-, and triphosphates of ddA. These ddA triphosphates act as substrate and inhibitor of HIV reverse transcriptase substrate and inhibitor of HIV reverse transcriptase thereby blocking viral DNA synthesis and suppressing HIV replication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159643\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Subject to degradation by acidic pH of stomach; some formulations are buffered to resist acidic pH; &le;55% reduction in peak plasma concentration is observed in presence of food. Delayed release capsules contain enteric-coated beadlets which dissolve in the small intestine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Extensive intracellular distribution</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CSF/plasma ratio: Infants 8 months to Adolescents 19 years: 46% (range: 12% to 85%); Adults: 21%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d </sub>(apparent):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Age-based:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants 8 months to Adolescents 19 years: 28 &plusmn; 15 L/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults: 43.7 &plusmn; 8.9 L/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-based:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 20 kg to &lt;25 kg: 98 &plusmn; 30 L</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 25 kg to &lt;60 kg: 155 &plusmn; 55 L</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;60 kg: 363 &plusmn; 138 L</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults &ge;60 kg: 308 &plusmn; 164 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &lt;5%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Has not been evaluated in humans; studies conducted in dogs show extensive metabolism with allantoin, hypoxanthine, xanthine, and uric acid being the major metabolites found in urine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Variable and affected by the presence of food in the GI tract, gastric pH, and the dosage form administered</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 8 months to Adolescents 19 years: 25% &plusmn; 20%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 42% &plusmn; 12%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Newborns (1 day old): 2 &plusmn; 0.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 2 weeks to 4 months: 1.2 &plusmn; 0.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 8 months to Adolescents 19 years: 0.8 &plusmn; 0.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults with normal renal function: 1.5 &plusmn; 0.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intracellular: Adults: 25 to 40 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Elimination: Increased as CrCl decreased</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 20 kg to &lt;25 kg: 0.75 &plusmn; 0.13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 25 kg to &lt;60 kg: 0.92 &plusmn; 0.09 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;60 kg: 1.26 &plusmn; 0.19 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &ge;60 kg: 1.19 &plusmn; 0.21 hours; 2 &plusmn; 0.3 hours (renal impairment [CrCl &lt;30 mL/minute]); 4.1 &plusmn; 1.2 hours (dialysis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Delayed release capsules: 2 hours; Powder for suspension: 0.25 to 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Unchanged drug excreted in urine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 8 months to Adolescents 19 years: 18% &plusmn; 10%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 18% &plusmn; 8%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159647\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Didanosine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $185.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $236.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (30): $368.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Videx EC Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (30): $162.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $259.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $330.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (30): $515.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Videx Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (100 mL): $66.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (200 mL): $145.18</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F159651\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bandotan (AR);</li>\n      <li>Bristol-Videx EC (CO);</li>\n      <li>Cipladinex (CO);</li>\n      <li>Didasten (MX);</li>\n      <li>Dinex (IN);</li>\n      <li>Dinex EC (PE);</li>\n      <li>Divir (PY);</li>\n      <li>Dycon-SR (LK);</li>\n      <li>Nyzonadyd (UA);</li>\n      <li>Vidanovir (HN);</li>\n      <li>Videx (AT, AU, BE, CL, CN, CY, CZ, DE, DK, EE, EG, ES, FR, GB, GR, HR, ID, IE, IT, LB, MY, NL, PL, PT, RU, SE, SI, TR, TW, UY, VE, VN, ZA);</li>\n      <li>Videx DDI (CO);</li>\n      <li>Videx EC (AU, BB, BG, CH, EE, FI, HK, HU, IE, LU, MT, MX, MY, NZ, PE, RO, SE, SG, SI, SK, TH, TW, VN);</li>\n      <li>Videx EC SR (KR);</li>\n      <li>Videx Pediatric (HK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abreu T, Plaisance K, Rexroad V, et al, &quot;Bioavailability of Once- and Twice-Daily Regimens of Didanosine in Human Immunodeficiency Virus-Infected Children,&quot; <i>Antimicrob Agents Chemother</i>, 2000, 44(5):1375-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/didanosine-pediatric-drug-information/abstract-text/10770783/pubmed\" target=\"_blank\" id=\"10770783\">10770783</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balis FM, Pizzo PA, Butler KM, et al, &ldquo;Clinical Pharmacology of 2&prime;, 3&prime;-Dideoxyinosine in Human Immunodeficiency Virus-Infected Children,&rdquo; <i>J Infect Dis</i>, 1992, 165(1):99-104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/didanosine-pediatric-drug-information/abstract-text/1727902/pubmed\" target=\"_blank\" id=\"1727902\">1727902</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butler KM, Husson RN, Balis FM, et al, &ldquo;Dideoxyinosine in Children With Symptomatic Human Immunodeficiency Virus Infection,&rdquo; <i>N Engl J Med</i>, 1991, 324(3):137-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/didanosine-pediatric-drug-information/abstract-text/1670591/pubmed\" target=\"_blank\" id=\"1670591\">1670591</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &quot;Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,&quot; April 8, 2015. Available at <a href=\"http://www.aidsinfo.nih.gov/\" target=\"_blank\">http://www.aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. April 2017. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Accessed November 14, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King JR, Nachman S, Yogev R, et al, &quot;Single-Dose Pharmacokinetics of Enteric-Coated Didanosine in HIV-Infected Children,&quot; <i>Antivir Ther</i>, 2002, 7(4):267-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/didanosine-pediatric-drug-information/abstract-text/12553481/pubmed\" target=\"_blank\" id=\"12553481\">12553481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kovari H, Ledergerber B, Peter U, et al, &quot;Association of Noncirrhotic Portal Hypertension in HIV-Infected Persons and Antiretroviral Therapy With Didanosine: A Nested Case-Control Study,&quot; <i>Clin Infect Dis</i>, 2009, 49(4):626-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/didanosine-pediatric-drug-information/abstract-text/19589079/pubmed\" target=\"_blank\" id=\"19589079\">19589079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McKinney RE Jr, Rodman J, Hu C, et al, &quot;Long-Term Safety and Efficacy of a Once-Daily Regimen of Emtricitabine, Didanosine, and Efavirenz in HIV-Infected, Therapy-Naive Children and Adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021,&quot; <i>Pediatrics</i>, 2007, 120(2):e416-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/didanosine-pediatric-drug-information/abstract-text/17646352/pubmed\" target=\"_blank\" id=\"17646352\">17646352</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Agency of Canada (PHAC), Canadian Guidelines on Sexually Transmitted Infection. Last modified December 2013. Available at http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php. Accessed December 30, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Videx EC (didanosine) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Videx pediatric powder for oral solution (didanosine) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; August 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12691 Version 178.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708701\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F159665\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F159666\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1052239\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442298\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1052232\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F159637\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F159622\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9845084\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1052243\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F159659\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1052242\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F159715\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F159713\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F159644\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F159626\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855998\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299187\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F159631\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F159661\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F159633\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F159648\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1052238\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F159625\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F159643\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F159647\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F159651\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12691|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=didanosine-drug-information\" class=\"drug drug_general\">Didanosine: Drug information</a></li><li><a href=\"topic.htm?path=didanosine-patient-drug-information\" class=\"drug drug_patient\">Didanosine: Patient drug information</a></li></ul></div></div>","javascript":null}